Literature DB >> 19418633

Inhibition of serotonin outflow by nociceptin/orphaninFQ in dorsal raphe nucleus slices from normal and stressed rats: Role of corticotropin releasing factor.

Cristiano Nazzaro1, Silvia Marino, Mario Barbieri, Anna Siniscalchi.   

Abstract

In the dorsal raphe nucleus (DRN) many inputs converge and interact to modulate serotonergic neuronal activity and the behavioral responses to stress. The effects exerted by two stress-related neuropeptides, corticotropin releasing factor (CRF) and nociceptin/orphaninFQ (N/OFQ), on the outflow of [(3)H]5- hydroxytryptamine were investigated in superfused rat dorsal raphe nucleus slices. Electrical stimulation (100 mA, 1 ms for 2 min) evoked a frequency-dependent peak of [(3)H]5- hydroxytryptamine outflow, which was sodium and calcium-dependent. Corticotropin releasing factor (1-100 nM), concentration-dependently inhibited the stimulation (3 Hz)-evoked [(3)H]5-hydroxytryptamine outflow; the inhibition by 30 nM corticotropin releasing factor (to 68 +/- 5.7%) was prevented both by the non selective CRF receptor antagonist alpha-helicalCRF(9-41) (alpha-HEL) (300 nM) and by the CRF(1) receptor antagonist antalarmin (ANT) (100 nM). The CRF(2) agonist urocortin II (10 nM) did not modify [(3)H]5- hydroxytryptamine outflow, ruling out the involvement of CRF(2) receptors. Bicuculline (BIC), a GABAA antagonist (10 microM), prevented the inhibitory effect of corticotropin releasing factor (30 nM), supporting the hypothesis that the inhibition was mediated by increased gamma-aminobutyric acid (GABA) release. Nociceptin/ orphaninFQ (1 nM-1 microM) exerted an antalarmin- and bicuculline-insensitive inhibition on [(3)H]5- hydroxytryptamine outflow, with the maximum at 100 nM (to 63+/- 4.2%), antagonized by the NOP receptor antagonist UFP-101 (1 microM). Dorsal raphe nucleus slices prepared from rats exposed to 15 min of forced swim stress displayed a reduced [(3)H]5-hydroxytryptamine outflow, in part reversed by antalarmin and further inhibited by nociceptin/orphaninFQ. These findings indicate that (i) both corticotropin releasing factor and nociceptin/orphaninFQ exert an inhibitory control on dorsal raphe nucleus serotonergic neurons; (ii) the inhibition by corticotropin releasing factor involves gamma-aminobutyric acid neurons; (iii) nociceptin/ orphaninFQ inhibits dorsal raphe nucleus serotonin system in a corticotropin releasing factor- and gamma-aminobutyric acid-independent manner; (iv) nociceptin/orphaninFQ modulation is still operant in slices prepared from stressed rats. The nociceptin/orphaninFQ-NOP receptor system could represent a new target for drugs effective in stress-related disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19418633     DOI: 10.1016/j.neuint.2009.01.004

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  10 in total

1.  Regulation of opioid gene expression in the rat brainstem by 3,4-methylenedioxymethamphetamine (MDMA): role of serotonin and involvement of CREB and ERK cascade.

Authors:  Manuela Di Benedetto; Sussy del Carmen Bastías Candia; Claudio D'Addario; Elena Elettra Porticella; Chiara Cavina; Sanzio Candeletti; Patrizia Romualdi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-12-23       Impact factor: 3.000

2.  Gender differences in Nociceptin/Orphanin FQ-induced food intake in strains derived from rats prone (WOKW) and resistant (Dark Agouti) to metabolic syndrome: a possible involvement of the cocaine- and amphetamine-regulated transcript system.

Authors:  Serena Battistoni; Ingrid Kloting; Carlo Cifani; Maurizio Massi; Carlo Polidori
Journal:  Genes Nutr       Date:  2010-11-13       Impact factor: 5.523

Review 3.  Corticotropin releasing hormone and imaging, rethinking the stress axis.

Authors:  Carlo Contoreggi
Journal:  Nucl Med Biol       Date:  2014-11-26       Impact factor: 2.408

Review 4.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

5.  Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.

Authors:  Matteo Marti; Donata Rodi; Qin Li; Remo Guerrini; Stefania Fasano; Ilaria Morella; Alessandro Tozzi; Riccardo Brambilla; Paolo Calabresi; Michele Simonato; Erwan Bezard; Michele Morari
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

Review 6.  The Nociceptin Receptor as an Emerging Molecular Target for Cocaine Addiction.

Authors:  Kabirullah Lutfy; Nurulain T Zaveri
Journal:  Prog Mol Biol Transl Sci       Date:  2015-12-23       Impact factor: 3.622

7.  Swim stress enhances nociceptin/orphanin FQ-induced inhibition of rat dorsal raphe nucleus activity in vivo and in vitro: role of corticotropin releasing factor.

Authors:  Cristiano Nazzaro; Mario Barbieri; Katia Varani; Lorenzo Beani; Rita J Valentino; Anna Siniscalchi
Journal:  Neuropharmacology       Date:  2009-09-09       Impact factor: 5.250

Review 8.  Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists.

Authors:  Jong Yung Park; Suji Chae; Chang Seop Kim; Yoon Jae Kim; Hyun Joo Yi; Eunjoo Han; Youngshin Joo; Surim Hong; Jae Won Yun; Hyojung Kim; Kyung Ho Shin
Journal:  Korean J Physiol Pharmacol       Date:  2019-10-24       Impact factor: 2.016

Review 9.  Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders.

Authors:  Massimo Ubaldi; Nazzareno Cannella; Anna Maria Borruto; Michele Petrella; Maria Vittoria Micioni Di Bonaventura; Laura Soverchia; Serena Stopponi; Friedbert Weiss; Carlo Cifani; Roberto Ciccocioppo
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 6.208

10.  Nutritional state influences Nociceptin/Orphanin FQ peptide receptor expression in the dorsal raphe nucleus.

Authors:  Magdalena J Przydzial; Alastair S Garfield; Daniel D Lam; Stephen P Moore; Mark L Evans; Lora K Heisler
Journal:  Behav Brain Res       Date:  2009-09-16       Impact factor: 3.332

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.